TVRD_OUT_1 [2025-04-29 06:47:57 -0400] 4392 Bytes | 1229 tokens | Cum: 1229 tkns (15.36% of 8k)
==========================================================================

Adventure stirs the soul. 6:47 AM on Tue Apr 29, 2025, Tvardi Therapeutics (TVRD) is on the move—$18.85 to $21.02. Shall we explore the opportunity, or stand down? Analysis awaits.

--- COMPANY PROFILE ---
Company: Tvardi Therapeutics (TVRD)
IPO: 2025-04-16 (13 Days Ago)
Market Cap: $196,653,493
Shares Outstanding: 3,120,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Here’s a list of headlines for Tvardi Therapeutics:

Apr-14-25 11:50AM - Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics
Dec-27-24 07:00AM - Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split
Dec-18-24 07:00AM - Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement
Dec-18-24 07:00AM 06:45AM - Tessera gets sickle cell funding; Corvus shares slide on eczema data
Nov-14-24 07:31PM - Cara: Q3 Earnings Snapshot
Aug-15-24 01:55PM - Cara: Q2 Earnings Snapshot
Jul-11-24 07:00AM - Cara Therapeutics Announces Exploration of Strategic Alternatives
Jun-13-24 09:51AM - Chipotle, McDonald's initiated: Wall Street's top analyst calls
Jun-12-24 04:01PM - Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
May-13-24 08:55PM - CARA Stock Earnings: Cara Therapeutics Misses EPS, Beats Revenue for Q1 2024
May-13-24 08:55PM 05:10PM - Cara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates
May-13-24 08:55PM 04:07PM - Cara: Q1 Earnings Snapshot
May-13-24 08:55PM 04:01PM - Cara Therapeutics Reports First Quarter 2024 Financial Results
May-06-24 07:00AM - Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024
Apr-02-24 07:00AM - Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Mar-07-24 07:00AM - Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
Mar-07-24 07:00AM 06:40AM - 7 F-Rated Stocks to Sell in March 2024
Mar-05-24 09:07AM - Cara Therapeutics, Inc. (NASDAQ:CARA) Q4 2023 Earnings Call Transcript
Mar-05-24 09:07AM 07:51AM - Q4 2023 Cara Therapeutics Inc Earnings Call
Mar-04-24 08:51PM - CARA Stock Earnings: Cara Therapeutics Misses EPS, Misses Revenue for Q4 2023
Mar-04-24 08:51PM 05:10PM - Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates
Mar-04-24 08:51PM 04:21PM - Cara: Q4 Earnings Snapshot

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Tvardi Therapeutics (TVRD).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

TVRD_OUT_3 [2025-04-29 06:47:58 -0400] 1009 Bytes | 294 tokens | Cum: 1525 tkns (19.06% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-25T12:09:07Z - 12 Health Care Stocks Moving In Friday's Pre-Market Session - Alector (NASDAQ:ALEC), Atlantic Intern...
A2 - 2025-04-25T09:38:43Z - Why Coursera Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket - Azitra (AME...
A3 - 2025-04-15T20:26:39Z - Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics...
A4 - 2025-04-14T17:51:55Z - Cara Therapeutics Stock Jumps 10% After Announcing 1-for-3 Reverse Stock Split: Retail Sentiment Soa...
A5 - 2025-04-14T16:29:46Z - Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with ...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

TVRD_OUT_5 [2025-04-29 06:47:58 -0400] 1181 Bytes | 358 tokens | Cum: 1885 tkns (23.56% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Friday's Pre-Market Session - Alector (NASDAQ:ALEC), Atlantic International (NASDAQ:ATLN)**Date: 2025-04-25Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/45005980/12-health-care-stocks-moving-in-fridays-pre-market-sessionGainers Azitra AZTR shares rose 27.1% to $0.39 during Friday's pre-market session. The company's market cap stands at $5.8 million. aTyr Pharma ATYR stock moved upwards by 22.28% to $4.22. The market value of their outstanding shares is at $374.8 million. Sera Prognostics SERA stock moved upwards by 14.92% to $3.85. The company's market cap stands at $145.0 million. Kairos Pharma KAPA stock rose 11.37% to $0.95. The market value of their outstanding shares is at $15.8 million. Alector ALEC shares moved upwards by 10.12% to $1.3. The company's market cap stan

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TVRD_OUT_7 [2025-04-29 06:47:59 -0400] 1181 Bytes | 350 tokens | Cum: 2237 tkns (27.96% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): ds at $128.7 million. Maze Therapeutics MAZE stock increased by 9.74% to $8.45. The company's market cap stands at $369.9 million. Losers Lexaria Bioscience LEXX shares declined by 31.4% to $1.16 during Friday's pre-market session. The company's market cap stands at $20.3 million. Intensity Therapeutics INTS shares declined by 29.46% to $0.64. The company's market cap stands at $9.6 million. Tvardi Therapeutics TVRD stock decreased by 21.35% to $14.0. The company's market cap stands at $130.9 million. VYNE Therapeutics VYNE stock decreased by 20.22% to $1.5. The market value of their outstanding shares is at $22.1 million. Atlantic International ATLN shares fell 15.9% to $3.81. The market value of their outstanding shares is at $237.8 million. Precipio PRPO shares fell 15.31% to $5.7. The market value of their outstanding shares is at $8.4 million. See Also: www.benzinga.com/money/best-h

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TVRD_OUT_9 [2025-04-29 06:47:59 -0400] 1060 Bytes | 351 tokens | Cum: 2590 tkns (32.38% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): ealthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALECAlector Inc$1.288.19%Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full ScoreEdge RankingsMomentum2.70Growth-Quality-Value87.69Price TrendShortMediumLongOverviewATLNAtlantic International Corp$3.80-16.1%ATYRaTyr Pharma Inc$3.40-1.44%AZTRAzitra Inc$0.386926.4%INTSIntensity Therapeutics Inc$0.7200-20.0%KAPAKairos Pharma Ltd$0.950011.4%LEXXLexaria Bioscience Corp$1.56-7.69%MAZEMaze Therapeutics Inc$8.398.96%PRPOPrecipio Inc$6.00-10.8%SERASera Prognostics Inc$3.535.37%TVRDTvardi Therapeutics Inc$14.00-21.4%VYNEVYNE Therapeutics Inc$1.87-0.53%Market News and Data brought to you by Benzinga APIs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TVRD_OUT_11 [2025-04-29 06:48:01 -0400] 238 Bytes | 59 tokens | Cum: 2651 tkns (33.14% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

TVRD_OUT_13 [2025-04-29 06:48:01 -0400] 251 Bytes | 78 tokens | Cum: 2732 tkns (34.15% of 8k)
==========================================================================

You just read a chunk of S1.
You may now:
- Say "MOR" to continue this article
- Say "S2", "S3", etc. to request another
- Or say "NEX" to move to the next source

You are allowed up to 6 articles from this list. If you’re ready to move on, say NEX.

TVRD_OUT_15 [2025-04-29 06:48:07 -0400] 6634 Bytes | 1740 tokens | Cum: 4474 tkns (55.93% of 8k)
==========================================================================

This is our set of metrics for Tvardi Therapeutics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+------------------------+
| Volume: 69,259 | Perf Month: 26.75% | Option/Short: No / Yes | Sales Y/Y TTM: -65.96% |
+--------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 10.07K | Perf Quarter: 16.97% | Short Float: 0.38% | ROE: -270.01% |
+--------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 7.57 | Index: - | Short Ratio: 2.35 | ROI: -177.81% |
+--------------------+-----------------------+------------------------+------------------------+
| RSI (14): 69.32 | Market Cap: 196.65M | Short Interest: 0.02M | Sales Surprise: 26.80% |
+--------------------+-----------------------+------------------------+------------------------+
| ATR (14): 2.04 | Shs Outstand: 9.36M | Beta: 0.23 | EPS Surprise: -40.70% |
+--------------------+-----------------------+------------------------+------------------------+
| SMA20: 28.64% | Shs Float: 6.26M | Sales Q/Q: -51.56% | P/E: - |
+--------------------+-----------------------+------------------------+------------------------+
| SMA50: 33.97% | Inst Own: 3.94% | Sales past 5Y: 92.45% | Earnings: - |
+--------------------+-----------------------+------------------------+------------------------+
| SMA200: 62.43% | Insider Own: 33.09% | Employees: 10 | |
+--------------------+-----------------------+------------------------+------------------------+
| Perf Week: 20.32% | Insider Trans: -0.15% | Debt/Eq: - | |
+--------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading by Tvardi Therapeutics officers or majority shareholders (if available).

Inside Trans: Tvardi Therapeutics, Inc. (TVRD) by Smith Cynthia (Unknown Title) on 2025-04-17
- Stock Option (right to buy): 12000 shares at $0 (D)

Inside Trans: Tvardi Therapeutics, Inc. (TVRD) by WYZGA MICHAEL S (Unknown Title) on 2025-04-17
- Stock Option (right to buy): 12000 shares at $0 (D)

Inside Trans: Tvardi Therapeutics, Inc. (TVRD) by Wirk Shaheen (Unknown Title) on 2025-04-17
- Stock Option (right to buy): 12000 shares at $0 (D)

Inside Trans: Tvardi Therapeutics, Inc. (TVRD) by Shiff Susan Ph.D. (Unknown Title) on 2025-04-17
- Stock Option (right to buy): 12000 shares at $0 (D)

Inside Trans: Tvardi Therapeutics, Inc. (TVRD) by Alibhai Imran Nizamudin (Chief Executive Officer) on 2025-04-17
- Employee Stock Option (right to buy): 182320 shares at $0 (D)

Inside Trans: Tvardi Therapeutics, Inc. (TVRD) by Kauh John Saewook M.D. (Chief Medical Officer) on 2025-04-17
- Employee Stock Option (right to buy): 36210 shares at $0 (D)

Inside Trans: Tvardi Therapeutics, Inc. (TVRD) by Conn Avi Daniel (Chief Financial Officer) on 2025-04-17
- Employee Stock Option (right to buy): 43547 shares at $0 (D)

Inside Trans: Tvardi Therapeutics, Inc. (TVRD) by Chen Yixin (VP, Chem, Mfg and Ctrls) on 2025-04-17
- Employee Stock Option (right to buy): 7213 shares at $0 (D)

Inside Trans: Tvardi Therapeutics, Inc. (TVRD) by O'Brien Stephen Paul (Principal Accounting Officer) on 2025-04-17
- Employee Stock Option (right to buy): 7213 shares at $0 (D)

Inside Trans: Tvardi Therapeutics, Inc. (TVRD) by Larson Jeffrey Leroy (SVP, Research & Development) on 2025-04-17
- Employee Stock Option (right to buy): 10820 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 21.02
Average Volume: 33848.88
30-Day High: 21.02
30-Day Low: 17.0391
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Tvardi Therapeutics (TVRD).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Tvardi Therapeutics.

2) MARKET_SCORE[]
This conversation was initiated because TVRD is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for TVRD.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, TVRD could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect TVRD to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Tvardi Therapeutics.

11) ETHICAL_RATING[]
Rate Tvardi Therapeutics’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Tvardi Therapeutics.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

TVRD_IN_17 [2025-04-29 06:48:08 -0400] 126 Bytes | 29 tokens | Cum: 4714 tkns (58.93% of 8k)
==========================================================================

====================================
[2025-04-29 06:48:08] # Analysis Completed
Elapsed Time: 11.96 seconds